Evidence mapPaperPMID 37552330Full record

Trial reportEuropean journal of nutrition2023

The effect of vitamin K4 supplementation on insulin resistance in individuals with type 2 diabetes: a double-blind randomised placebo-controlled clinical trial.

Amani M Ali, Maggie M Abbassi, Nirmeen A Sabry, May Fawzi, Shrook Mousa

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04285450 (The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients), which is not on this map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04285450 nacompletednot on this map

The Clinical Effect of Vitamin K Administration in Type 2 Diabetic Patients

TypeinterventionalSponsorCairo UniversityRan2019 to 2022Enrolled106ConditionsDiabetes Mellitus, Type 2ArmsVitamin K, Placebo
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amani M AliDepartment of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt. amany.mohamed@pharma.cu.edu.eg.ORCID http://orcid.org/0000-0001-6155-2819
Maggie M AbbassiDepartment of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-5956-8990
Nirmeen A SabryDepartment of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0003-0478-0772
May FawziDepartment of Internal Medicine, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0001-8672-2458
Shrook MousaDepartment of Internal Medicine, Kasr Alainy Faculty of Medicine, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-9720-8240
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to assess the possible clinical effects of vitamin K4 supplementation in individuals with type 2 diabetes namely insulin resistance, glycaemic control, and lipid profile.

methodsThis was a prospective randomised double-blind placebo-controlled clinical trial. A total of 106 patients were randomised to receive either 1 mg of vitamin K4 (menadiol diacetate) or placebo for 24 weeks.

resultsNinety patients (n = 45 in each study group) were included in the final analysis. After 24 weeks, homeostatic model assessment of insulin resistance (HOMA-IR) (16.54 ± 7.81 vs. 29.09 ± 36.56, P = 0.027) and fasting serum insulin (FSI) (6.86 ± 3.45 vs. 11.13 ± 12.66 µU/ml, P = 0.032) were significantly lower in the vitamin K group compared to placebo. Additionally, triglycerides (TG) (144.94 ± 50.7 vs. 172.8 ± 101.5 mg/dl, P = 0.031) and very low-density lipoproteins (VLDL) levels (28.9 ± 9.88 vs. 34.6 ± 20.30 mg/dl, P = 0.027) decreased significantly in the vitamin K group after 24 weeks compared to baseline. Moreover, more patients in the vitamin K group (35.6%) had their antidiabetic medication doses reduced after 24 weeks compared to placebo (13.3%, P = 0.029).

conclusionVitamin K4 supplementation for 24 weeks is capable of improving insulin resistance and TG levels in individuals with type 2 diabetes. In addition, the improvement in insulin resistance was reflected in the decrease in antidiabetic medication doses. However, it did not affect fasting plasma glucose (FPG) or glycated haemoglobin (HbA

trial registrationThe study was registered on clinicaltrials.gov with ID: NCT04285450.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceBlood GlucoseDietary SupplementsDouble-Blind MethodHumansHypoglycemic AgentsInsulinProspective StudiesVitamin KVitaminsBlood GlucoseHypoglycemic AgentsInsulinVitamin KVitaminsDiabetes mellitusInsulin resistanceLipid profileType 2 diabetesVitamin K

Identifiers

PMID37552330
PMCPMC10611861
OpenAlexW4385644836

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.